TBK1 and digestive system carcinoma: Of clinical relevance, data from the villin+ intestinal epithelium-specific knockout of Tbk1 suggest that the use of TBK1 inhibitors would be contraindicated in at least some patients with gastrointestinal carcinomas [219].